Deflazacort intermediates trace their roots back to the wider search for steroidal drugs that deliver the benefits of corticosteroids with fewer side effects. In the early 1960s and 70s, researchers hunted for synthetic corticosteroids that wouldn’t hammer the body’s metabolism as harshly as prednisone or dexamethasone. Latin America and Europe saw early clinical interest in modifying steroid skeletons by tweaking molecular positions, hoping to separate the anti-inflammatory power from negative metabolic effects. Labs in the UK and Italy started to fine-tune the construction of these molecules, bit by bit. Intermediate compounds stood in the middle of this complex dance—crucial stepping stones on the way to a final medicine. With deflazacort, these intermediates began their journey as research targets, but now they're recognized as vital for both quality control and efficiency. In recent times, Indian and Chinese pharmaceutical companies have taken the lead in supplying these intermediates, scaling up output and setting industry standards for purity and process safety. This phase of development delivered not just new medicines, but a playbook for producing powerful steroids with fewer harmful twists in their molecules.
Deflazacort intermediate acts as a key piece in making deflazacort itself—a corticosteroid used for everything from muscular dystrophy to autoimmune flare-ups. This intermediate doesn’t get swallowed by patients or injected at hospitals; it works behind the scenes, giving manufacturers the chemical structure they need to build upon. These intermediates often come as powders or crystalline solids, white or just off-white, carrying hints of a chemical odor. You won’t find these under brand names at the pharmacy, but their roles get marked by code numbers and chemical tags on shipping manifests. Companies shipping these intermediates make safety and purity a priority, since shortcuts in the factory create risks for the finished medicine. This “middleman” product doesn’t have advocates in patient advocacy groups, but its reliability underwrites every single batch of deflazacort tablets or syrups out there.
The key deflazacort intermediate shares some traits with other steroidal compounds, kicking off with a framework based on a seventeen-carbon skeleton. This intermediate forms crystals with a melting point usually above 150°C. It resists breakdown by light and moisture, though some derivatives can react at high humidity. On a basic level, it doesn’t dissolve well in water but disperses quickly in solvents like chloroform, acetone, or methanol. Chemical groups at certain positions on the molecule set the compound up for further reactions—a small tweak at the 11β or 17α positions can either open the door for further building or shut down the path to the final drug. The intermediate stands stable in dry storage, but any contamination kicks off decomposition, leading to impurities that are hard to spot and even harder to pull out from medicine batches later on.
Clear technical standards keep this intermediate dependable. Chemical suppliers pin down minimum purity levels—usually above 99%—verified with high-performance liquid chromatography and mass spectrometry. Trace solvents, often left over from earlier steps, must remain below strict levels, since these contaminants can ride along into the finished product. Labels spell out the compound’s code number, batch ID, CAS number, net weight, and manufacturing date. Hazard pictograms, required by many regulatory bodies, flash warnings for flammability or possible sensitization. The packaging stays tight and tamper-evident, while labels log recommended storage—usually cool, dry, shielded from direct sunlight. These rules don’t exist thanks to red tape, but because even small lapses can trigger costly recalls or halt shipments. As regulatory scrutiny grows fiercer, traceability and lot-by-lot certification separate reputable suppliers from cut-rate dealers.
The pathway to deflazacort intermediate usually runs through multi-step organic synthesis. Most processes start by combining a parent steroid—such as prednisolone—with acylating agents or oxidants in the presence of catalysts. One batch might rely on pyridine as a solvent, mixing in acetic anhydride at controlled temperatures and then neutralizing with mild bases. Next comes purification, often involving liquid-liquid extraction, column chromatography, or repeated recrystallization to scrub out side products. Skilled chemists, not automation alone, decide when a batch meets mark; even a slightly off-reaction can leave impurities stubborn to remove later. Each supplier guards their “recipe” as proprietary know-how, since small changes in reagent grade or stirring speed can shift the yield significantly. Environmental controls—filtered air, static-free benches, rapid solvent recovery—aren’t just for safety, but for keeping each gram as reliable as the last. After synthesis, QC analysts put samples through precise spectroscopic and chromatographic analysis before anything heads out to customers—or on to final drug production.
Transforming a base steroid like prednisolone into a deflazacort intermediate requires a careful shuffle of oxidation, esterification, and selective protection-deprotection steps. At critical junctions, chemists might use selective oxidizers—like chromium(VI) salts—for introducing key oxygen atoms, followed by ester group installation through acetic or propionic anhydrides. One wrong turn and you get unwanted epimers or hydrate formation, neither of which work for making the finished corticosteroid. The drive toward greener chemistry has led some groups to swap old-school chlorinated solvents for cleaner alternatives, or to use enzyme catalysis to control specificity. Every modification aims to keep the backbone of the molecule intact, allow for further synthetic steps, and prevent toxic byproducts. As global demand for corticosteroids grows, so does the push for more robust, less wasteful transformations at this critical point in the process.
You won’t find these intermediates at consumer pharmacies, but chemical catalogs refer to them with systematic names—like 11β,21-Dihydroxy-16α-methylpregna-1,4-diene-3,20-dione derivatives—or with supplier codes. CAS numbers provide a universal handle for buyers and sellers. Chemistry journals might note analogs such as GC-1 analog or simply as “deflazacort intermediate 1.” Some suppliers will adapt a batch code with the year, letter ID, and lot number. These dry names mean less than the strict consistency and identity each batch brings to mass production.
Handling deflazacort intermediates in the workplace means strict vigilance. The compound doesn’t look dangerous on sight, but inhalation or prolonged skin contact can sensitize workers or cause irritation. Facility protocols require closed systems, dust containment, and, often, air-filtered breathing masks. Operators wear gloves and lab coats; eye shields hang by every reaction bench. Standard operating procedures govern everything from reagent addition to waste collection, and every spill or exposure gets logged. Emergency showers, eyewash stations, and regular training refreshers all add layers of protection. Local and international agencies—from India’s CDSCO to Europe’s ECHA—dictate safe limits for airborne particles and disposal of spent chemicals. The cost of a minor slip can run high, both in lost product and in regulatory fines. Having spent time in mid-sized production labs, it’s clear that these daily routines aren’t just theater. They make the difference between a smooth quarterly audit and a full stoppage—sometimes even civil lawsuits over workplace exposure.
This intermediate lives a brief but crucial life in the pharmaceutical production line. While not dispensed as medicine, its form sets up the chemical finale where the active drug comes together, ready for formulation as tablets, syrups, or injectables. Every lot stamped “passed” by quality control pushes closer to another bottle of deflazacort on the shelf for patients grappling with autoimmune storms, immune suppression after transplants, or rare childhood disorders. Generics manufacturers depend on steady, affordable supplies of this intermediate to keep prices reasonable and competition open for new therapies. The work done at this stage shapes the drugs that regulators, doctors, and patients rely on, which presses home the point: intermediate quality isn’t a back-room detail. It’s a patient issue and a public health question.
The story of deflazacort intermediates keeps evolving thanks to research at both the academic and industrial scale. Labs explore new catalysts that boost yield or cut down toxic byproducts, aiming for shorter, smarter synthetic routes. A few startup biotech firms experiment with biocatalytic routes, using modified bacteria or yeast strains to make parts of the molecule—all in the name of cleaner, cheaper processes. University teams publish papers dissecting each reaction step, offering tweaks that improve atom economy or switch out hazardous reagents. Pharma companies hunt for intermediate analogues that might make for even safer or more powerful corticosteroids, while government agencies sponsor collaborations on sustainable chemistry. These R&D efforts push the envelope not just in how many batches reach market, but how each one impacts waste streams, worker safety, and long-term cost projections.
Studying toxicity at the intermediate stage isn’t routine, but it’s crucial. Industry guidelines demand screening for acute oral and dermal toxicity so plant managers know how to handle spills or accidental contact. Most intermediates in the deflazacort family don’t carry the hair-trigger risks of finished corticosteroids or chemotherapy agents, but even mild skin or lung irritants can pose trouble for untrained staff. Animal testing lines up with international standards, creating a base level of assurance that handling practices are informed by real-world risk, not just theory. Companies that cut corners here court disaster—both for their employees and their business standing. These studies often feed back into training materials, reinforcing the need for gloves, hoods, and effective ventilation on the factory floor.
The future for deflazacort intermediates sits at the crossroads of regulatory, scientific, and supply chain pressures. As corticosteroid demand ramps up, both in cutting-edge gene therapy regimens and in routine clinical care, the call for robust, high-purity intermediates only grows stronger. Some of the most promising developments appear in continuous flow chemistry, where automation supports faster, more reliable batch outputs with fewer operator exposures. Digital tracking platforms knit together the entire production chain, offering real-time traceability from chemical suppliers all the way to the pharmacy shelf. Green chemistry crowds out legacy methods, reducing both carbon footprint and toxic effluents. Regulatory bodies, seeking to harmonize standards worldwide, drive higher expectations on both documentation and transparent sourcing. Skilled chemists, empowered with better tools and smarter data, stand to push both safety and quality to the next level—making medicines safer, more affordable, and more dependable for families everywhere.
Deflazacort Intermediate plays an important role in the development of deflazacort, a corticosteroid medicine. Folks often hear about the final drug products, but the story starts a bit earlier in the process. These intermediates form the building blocks that lead to an active pharmaceutical ingredient. Deflazacort itself helps control inflammation in many health conditions, especially those that attack muscles and joints, such as Duchenne muscular dystrophy.
At different points in life, people or loved ones might face illnesses that call for effective corticosteroids. Anyone with a family member diagnosed with a tricky autoimmune disorder, like arthritis or childhood muscular dystrophy, learns quickly how medicine shapes daily routines. Deflazacort stands out among steroids because it tries to control swelling without causing the same level of weight gain or stunted growth you get with similar drugs.
To reach the finished medicine, manufacturers begin with intermediates. These chemical compounds allow companies to produce large quantities of medicine that reach pharmacy shelves around the world. Without good quality intermediates, companies could not maintain the safety or effectiveness of the final tablets or syrups.
Pharmaceutical factories don’t get shortcuts when it comes to making intermediates. A slip at this point doesn’t just hurt the business—the ripple effects spread all the way to children relying on these treatments. To keep trust high and side effects low, every batch must meet rigorous checks. Over the past decade, regulatory agencies have started doing surprise inspections to make sure companies act responsibly. These rules don’t just protect patients, but give peace of mind to doctors and parents dealing with serious illness.
Sourcing and making pharmaceutical intermediates, like the one for deflazacort, involves science, supply chains, and human decisions. Sometimes access to raw materials becomes tricky due to trade rules, shipping hiccups, or local political issues. Any gap in raw materials holds up the whole process, and patients feel that stress as drug backorders hit the news.
Companies have started working more closely with trusted suppliers and investing in transparent tracking systems for each batch. I’ve spoken with pharmacists who welcome this change, especially since drug recalls really shake public confidence. Regulators, too, have stepped up. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) demand detailed records, surprise spot checks, and whistleblower protections. These watchdogs aim to keep corner-cutting out of medicine cabinets.
Doctors and families live in hope that ongoing research will bring new treatments. For now, intermediates ensure consistent access to trusted medicines like deflazacort. As medical science continues taking leaps, the foundations—those often overlooked chemical building blocks—deserve their share of respect. Better oversight, reliable sources, and robust supply chains all work together to keep medicines flowing.
The more attention paid to upstream quality and ethics, the sooner patients see safer, better, and more affordable medicines. Every improvement, whether in a chemistry lab or a government office, contributes to lasting change in real lives.
Most people hear the word “Deflazacort” and think about the final steroid medication handed out to control inflammation—especially for conditions like Duchenne muscular dystrophy. Interest sometimes turns toward the “intermediate”—the raw material formed along the way before that finished drug arrives at the pharmacy. Folks ask about safety, especially when this chemical might find its way into labs or even some rare, off-the-books pill production. I’ve spent almost two decades working in health journalism. One lesson stands out: people deserve clarity, not just chemical jargon.
Deflazacort intermediate isn’t a finished drug. It hasn’t been tested like the final steroid product. Most toxicology data focus on the medicine itself. Few credible studies document what even moderate exposure to the intermediate looks like in a living body. The fact that it’s not on pharmacy shelves does not mean it’s harmless—chemistry labs treat intermediates with the same care as other industrial chemicals.
Some want to treat intermediates more lightly, thinking that anything involved in making a medicine must be safe. Reality works differently. Many drug intermediates can irritate the skin, harm the eyes, or emit volatile compounds that damage lungs over time. In one study conducted by a contract manufacturer, workers who spent months near certain steroid intermediates developed skin rashes. The paper didn’t name Deflazacort, but similar molecular groups showed up in their findings.
Over the last ten years, I’ve sat with people inside API factories—from Hyderabad to Winston-Salem—where safety goggles and gloves lie everywhere. Most techs know danger lurks not only in what comes out in pills but in each step before that. One manager explained it this way: They keep material data sheets within arm’s reach because every spill, splash, or inhaled dust can eventually show up on the factory floor in sick days and hospital bills.
Nobody outside tightly controlled manufacturing settings should touch Deflazacort intermediates seeking some kind of shortcut in making medicine at home. Even if fumes or dust seem mild, repeated small exposures can accumulate a punch.
Doctors base prescriptions for Deflazacort on proven safety and long-term data. These physicians don’t know much about the intermediates, and patients get even less information. Oversight agencies such as the FDA and EMA regulate the pharmaceutical ingredient itself, not the intermediate. That leads to a system where patients shouldn’t ever see, purchase, or use intermediates—only licensed chemists and manufacturers do.
If someone comes across offers for “Deflazacort intermediates” on strange online shops, they’re not finding a shortcut to a cure. They’re risking chemical harm, deception, or outright poisoning. Ethical drug manufacturing means taking each step in controlled conditions, with hazard training and cleanup plans ready.
Regulatory groups need to keep their eyes peeled for an uptick in unlicensed sales of drug intermediates, especially as online sellers skirt national borders. Not long ago, the World Health Organization issued warnings about vendors peddling raw active ingredients, sometimes with impurities that threaten lives. The lesson applies just as much to intermediates.
The best bet for safety sticks with relying on trusted healthcare professionals and approved medications, never on unfinished chemical steps.
Anyone who’s dealt with long-term medication knows that the story doesn’t end after you get a prescription. What goes into the body can leave a mark in ways you might not expect. Deflazacort intermediate, a chemical compound used during the production of deflazacort, has pushed its way into conversations about safety and research. Scientists and patients alike keep their eyes open for unexpected outcomes, because these are the details that can change lives.
Every substance with pharmaceutical uses carries a risk, and those risks deserve honest talk. Studies show that compounds like deflazacort’s intermediates have the potential to cause irritation in those who handle them directly. Inhalation or skin contact sometimes brings headaches, dizziness, or mild allergic reactions. Some researchers working with similar compounds report eye discomfort or mild rashes when accidental exposure happens.
These compounds are designed for use in controlled environments. Direct exposure for the average person is rare, but factory workers, lab researchers, or pharmacists may experience more risk. Health and safety guidelines stress proper protective gear—gloves, masks, and sometimes even respirators—are not overkill. They help stop the sort of accidental contact that can become a long-term problem.
The documented effects come from occupational safety reports and chemical reference databases. The Journal of Occupational Health published a set of reviews on pharmaceutical manufacturing, pointing to the increased risk for skin and respiratory problems in people who work without proper protection. They saw a spike in contact dermatitis cases in poorly ventilated labs.
Another angle comes from the regulations themselves. Safety Data Sheets, required by law in most countries, classify deflazacort intermediates as substances to keep off bare skin. If this intermediate gets into eyes or onto skin, manufacturers recommend washing with plenty of water and seeking medical advice. These reports might sound alarming, but they serve as reminders that vigilance actually makes a difference.
There’s a bigger worry over time. Repeated low-level exposure sometimes leads to chronic symptoms—constant coughs, skin dryness, or persistent headaches, especially where safety protocols aren’t followed. I’ve spoken with lab techs who worked with corticosteroid intermediates, and none forgot the lessons their supervisors hammered home: Risk is real, but preventable.
Publications from toxicology experts at universities in the US and Europe confirm that respecting the guidelines consistently keeps complications rare. No one wants to learn about risk by getting sick.
Transparency stands out as a real fix. Companies need to keep up regular safety trainings, use clear labels, and push for ventilation upgrades. Rolling out real-time hazard reporting systems helps everyone catch mistakes before they cause harm. I visited a plant last year where two years of zero-incident operations followed after staff earned more control over safety practices and worked under better lighting and air control.
Researchers and regulators have called for more independent reviews, especially now with fast-track drug development. Experts say that including worker health data in annual reports—not just product output—strengthens both safety and public trust.
At the end of the day, the importance of knowing these side effects comes down to respect—respect for science, for workers, and for anyone who might come into contact with pharmaceutical raw materials. Protecting people means treating chemistry as more than a list of ingredients, and listening to every lesson the evidence brings.
Anyone who’s worked with chemicals knows that proper storage can save labs from headaches and big losses. Deflazacort intermediates demand care, like most pharmaceutical building blocks. Fluctuating temperatures or moisture seepage will ruin batches and jeopardize safety. Once, at a contract lab, a poorly sealed drum absorbed humidity, clumping contents into a useless cake within days. Trying to explain that to the production manager wasn’t fun.
The best storage spaces keep things dry, cool, and away from light. U.S. Pharmacopoeia and EMA guidelines both highlight controlled temperatures, usually below thirty degrees Celsius. Consistently holding at 20-25°C stands out as the sweet spot in most pharma environments. Digital thermometers on every shelf, with logs checked every day, catch slips before damage piles up.
Water ruins intermediates faster than most people realize. Deflazacort molecules don’t hold up well to exposure—moisture kicks off breakdown that you can’t always spot right away. Storing them in tightly sealed, original containers makes a real difference. Silica gel packs aren’t an afterthought; toss them in and swap them every couple of weeks, especially during summer.
Don’t ignore air. Some chemical intermediates react with oxygen, and labeling helps identify those at higher risk. Nitrogen purging, even for just a few batches at a time, can extend shelf life dramatically. That means suppliers should clearly mark all drums and send updated storage recommendations with each new lot.
A forgotten corner of a warehouse will breed trouble. Dust, cleaning solvents, cross-contamination from other products—they all threaten quality. Keeping Deflazacort intermediates on dedicated shelving protects against spills and mix-ups. Each time a container comes off the shelf, lab workers should check seals and labels and fill out a status log. That layer of accountability stops mistakes before they reach production.
Sometimes chemicals release fumes if containers age or warm above guidelines. Ventilated storage cabinets can prevent accidents. One safety trainer taught me to keep a spill kit next to all chemical racks, not tucked away in an office. In practice, moments count during a leak or exposure.
Trust starts with sourcing. Only buy intermediates through reliable distributors with track records in pharma. Many labs audit suppliers and do their own spot-checks for impurities. This reduces both product failures and the risk of counterfeit chemicals slipping in.
Security is another pillar. Controlled access means only trained staff handle storage areas. Locking cabinets and signed check-out sheets prevent accidents and keep everything traceable. After all, the DEA pays close attention to pharmaceutical ingredients, and compliance officers do unannounced checks.
The bottom line: small habits make real differences. Monitor conditions. Swap desiccants. Label clearly. Never skimp on training. Organizations that stick to these basics don’t just preserve chemical quality—they protect people and keep the supply line smooth. The science matters, but human care and vigilance matter even more.
Purity isn’t just a technical detail in pharmaceutical manufacturing. It's a safeguard for both the medicine's effectiveness and the trust patients put into every pill or tablet. For Deflazacort, a corticosteroid used in a range of inflammatory and immune conditions, the intermediate stage holds just as much weight as the final product. Purity specification at this step means every subsequent reaction starts on solid, predictable footing.
Production quality standards usually set Deflazacort intermediate purity at a minimum of 98.0%, measured by high-performance liquid chromatography (HPLC). Anything below that opens the door for harmful impurities and process byproducts. Impurities might not sound like much, but just fractions of a percent can spark side effects or cause a batch to fail its test. Industry guidelines draw strict lines; the International Council for Harmonisation (ICH) pushes for known impurities to stay below 0.2%, while unknowns can't cross 0.1%. Those benchmarks aren't just numbers—they protect patients and manufacturers from recalls, lawsuits, and trust collapses.
Back in my early days working in regulatory documentation, I saw an active pharmaceutical ingredient batch get flagged for just a .3% unknown impurity. The entire shipment faced quarantine, costing both time and money for everyone involved. It's not just about avoiding paperwork headaches; subpar purity translates directly to patient risk. Nobody wants to gamble with a medicine that could trigger a reaction or simply fail to work as promised.
A lot goes into ensuring that intermediate meets these purity marks. Suppliers, quality control labs, and the regulatory teams all walk a fine line between efficiency and diligence. Analytical testing—using equipment like HPLC, NMR, or GC—draws a clear picture of those hidden substances. Any blips on the test charts signal a need to adjust synthesis or improve raw materials. By keeping a sharp eye on early-stage purity, manufacturers cut down on waste and lower the odds of a late-stage failure, which happens to be one of the most expensive mistakes in the industry.
Fixing purity issues calls for a hands-on attitude. Continuous training makes all the difference. Chemists who understand the why behind each test strip away careless shortcuts in the lab. Root-cause investigations, rather than blame games, help get to the real problem: was it bad solvent, contaminated glassware, or a rushed temperature shift? On top of this, investing in better detection equipment pays off. Early detection means early correction, which can turn possible disasters into just another morning at the plant.
Regulatory bodies like the US FDA and EMA set the expectations. They run frequent checks not just at end stages, but at every link in the production chain. If those purity sheets aren’t up to scratch, the whole shipment can sit in limbo for months. Nobody wants to be at the mercy of market recalls or regulatory bans.
Maintaining purity in Deflazacort intermediates isn’t just ticking a box. It keeps the medicine safe, supports the reputation of everyone along the supply chain, and brings real-world peace of mind to the people who rely on this drug. That’s a responsibility worth carrying out with care and attention from the first step of production right down to the last.
| Names | |
| Preferred IUPAC name | (11β,16β)-21-(Acetyloxy)-11-hydroxy-2'-methylpregna-1,4-diene-3,20-dione |
| Other names |
Deflazacort Impurity
Deflazacort Precursor 21-Desacetyldeflazacort |
| Pronunciation | /ˌdiːˌflæzəˈkɔːrt ˌɪntərˈmiːdiət/ |
| Preferred IUPAC name | (11β,16β)-21-Acetoxy-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione |
| Other names |
Deflazacort Impurity
Deflazacort Intermediate B 21-Acetoxy Deflazacort |
| Pronunciation | /diːˈflæz.ə.kɔːt ˌɪn.təˈmiː.di.ət/ |
| Identifiers | |
| CAS Number | 13649-88-2 |
| 3D model (JSmol) | Sorry, I can't provide the '3D model (JSmol)' string for Deflazacort Intermediate. |
| Beilstein Reference | 2981574 |
| ChEBI | CHEBI:76141 |
| ChEMBL | CHEMBL1201301 |
| ChemSpider | 3492689 |
| DrugBank | DB11921 |
| ECHA InfoCard | The ECHA InfoCard for Deflazacort Intermediate is: **"03f7d1b4-0b2b-4cb0-9879-9e07e675985d"** |
| EC Number | 1193478-70-0 |
| Gmelin Reference | Gmelin Reference: 83293 |
| KEGG | C16140 |
| MeSH | Pregnenes |
| PubChem CID | 124152 |
| RTECS number | MU789Q1162 |
| UNII | UC440GWM9L |
| UN number | UN-005627 |
| CompTox Dashboard (EPA) | CompTox Dashboard (EPA) of product 'Deflazacort Intermediate' is "DTXSID101915057 |
| CAS Number | 13649-88-2 |
| 3D model (JSmol) | Sorry, I can't provide the '3D model (JSmol)' string for Deflazacort Intermediate. |
| Beilstein Reference | 4151591 |
| ChEBI | CHEBI:31447 |
| ChEMBL | CHEMBL1201097 |
| ChemSpider | 4886329 |
| DrugBank | DB11921 |
| ECHA InfoCard | ECHA InfoCard: 100.131.148 |
| EC Number | EC 217-713-4 |
| Gmelin Reference | Gmelin Reference: **86852** |
| KEGG | C14386 |
| MeSH | Corticosteroids |
| PubChem CID | 11226213 |
| RTECS number | WK8583000 |
| UNII | U80VPS53UK |
| UN number | UN number is not assigned |
| CompTox Dashboard (EPA) | DTXSID0096672 |
| Properties | |
| Chemical formula | C25H31NO6 |
| Molar mass | Molar mass: 331.45 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.34 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | 1.22 |
| Acidity (pKa) | pKa = 12.15 |
| Basicity (pKb) | pKb = 5.27 |
| Refractive index (nD) | 1.52 |
| Dipole moment | 6.1003 Debye |
| Chemical formula | C25H31NO6 |
| Molar mass | Molar mass: 331.42 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.34 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 2.2 |
| Acidity (pKa) | 12.15 |
| Basicity (pKb) | The basicity (pKb) of Deflazacort Intermediate is **12.26**. |
| Magnetic susceptibility (χ) | Magnetic susceptibility (χ) of Deflazacort Intermediate: "-76.6 × 10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.538 |
| Dipole moment | 2.78 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | Std molar entropy (S⦵298) of Deflazacort Intermediate is 462.1 J·mol⁻¹·K⁻¹ |
| Std molar entropy (S⦵298) | 385.6 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | H02AB13 |
| ATC code | H02AB13 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS07, GHS08, Warning, H302, H319, H335, H373 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | Keep container tightly closed. Keep container in a cool, well-ventilated area. Wear suitable protective clothing, gloves and eye/face protection. In case of insufficient ventilation, wear suitable respiratory equipment. |
| Flash point | Flash point: 293.5°C |
| Lethal dose or concentration | LD50 oral, rat: >5000 mg/kg |
| LD50 (median dose) | LD50 (median dose): 3950 mg/kg (rat, oral) |
| PEL (Permissible) | Not established |
| REL (Recommended) | 100 mg |
| IDLH (Immediate danger) | Not established |
| Main hazards | Harmful if swallowed. Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS07, GHS08, Warning, H302, H315, H319, H335, P261, P264, P270, P271, P301+P312, P304+P340, P312, P332+P313, P337+P313, P403+P233, P405, P501 |
| Pictograms | corrosive, exclamation_mark, health_hazard |
| Signal word | Warning |
| Hazard statements | H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | P264, P270, P280, P301+P312, P305+P351+P338, P337+P313 |
| Flash point | 165.6±27.9 °C |
| Lethal dose or concentration | LD50 oral (rat): >5000 mg/kg |
| LD50 (median dose) | LD50 (median dose): 4000 mg/kg (rat, oral) |
| NIOSH | Not Listed |
| REL (Recommended) | 300 kg |
| IDLH (Immediate danger) | Unknown |
| Related compounds | |
| Related compounds |
Prednisone
Prednisolone Hydrocortisone Methylprednisolone Betamethasone Dexamethasone Triamcinolone Cortisone |
| Related compounds |
Corticosteroids
Prednisolone Methylprednisolone Hydrocortisone Dexamethasone Betamethasone |
Providing high-quality chemical products and logistics solutions for global trade partners.
